This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Waterloo directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein.
Communications biology · 2022
Latest funding
- $830,024
Ultrapotent and broadly neutralizing engineered biologics as therapeutics for SARS-CoV-2
CIHR · 2022 · Nominated PI
- $125,000
Genetic engineering of T cells to target pathogenic antigen-presenting cells in Primary Biliary Cholangitis treatment
SSHRC · 2022 · Co-investigator
1 publications.
Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein.
Xiang J, Su J, Lan Q, Zhao W, Zhou Y, Xu Y, Niu J, Xia S, Qi Q, Sidhu S, Lu L, Miersch S, Yang B
Ultrapotent and broadly neutralizing engineered biologics as therapeutics for SARS-CoV-2
Principal investigators: Sidhu, Sachdev S
Keywords: Antibody Therapeutic; Antiviral Antibody; Covid-19; Emerging Variants Of Concern; In Vivo Efficacy; Multispecific Antibody; Multivalent Antibody; Protein Engineering; Sars-Cov-2; Spike Protein
Genetic engineering of T cells to target pathogenic antigen-presenting cells in Primary Biliary Cholangitis treatment
Principal investigators: Sokke Umeshappa, Channakeshava
Keywords: Primary Biliary Cholangitis; Disease-specific treatment; Synthetic biology; Chimeric antigen receptor T cells; peptide-presenting MHC II molecules; Antigen-presenting cells; Chronic diseases; E2 component of the pyruvate dehydrogenase complex (PDC-E2)
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.